INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Brain & Mood desk →

1,209 studies · page 50 of 51

2001 / Three randomized controlled trials

Red Bull energy drink enhanced physical endurance and mental performance in three trials.

Across three studies involving 36 volunteers, consumption of Red Bull Energy Drink was evaluated against control beverages. The energy drink improved cycle ergometer aerobic endurance (maintaining 65-75% maximum heart rate) and anaerobic output at maximum speed (P < 0.05). Participants also demonstrated better choice reaction times, concentration via number cancellation, immediate recall memory, and higher subjective alertness.

Alford C, Cox H, Wescott R Amino Acids, 2001. PMID 11665810

2000 / Intervention trial (three conditions)

Daily bathing and hot footbaths before sleeping shortened sleep onset latency and improved subjective sleep sensations in healthy women in winter.

Nine healthy female volunteers were evaluated under three sleep conditions in winter: sleep after bathing, sleep after a hot footbath, and sleep without either treatment. Rectal temperature increased by approximately 1.0 degree C after bathing but not after the footbath compared to control, while mean skin temperature increased in both treatment conditions. Sleep onset latency was shortened and body movements during the first 30 minutes of sleep were reduced under both treatment conditions compared with control. REM sleep decreased with bathing compared to footbath, stage 3 sleep was greater after footbath compared to control, and subjective sleep sensations were better following both treatments.

Sung EJ, Tochihara Y J Physiol Anthropol Appl Human Sci, 2000. PMID 10979246

2000 / 3-month open-label study

Oral NADH supplementation for 3 months showed no evidence of cognitive improvement in patients with mild to moderate dementia.

Researchers conducted a 3-month open-label study administering 10 mg/day of oral reduced nicotinamide adenine dinucleotide (NADH) to 25 patients with mild to moderate dementia alongside their current cholinomimetic medication. Among the 19 patients who completed the study, no evidence was found for any cognitive effect assessed by established psychometric tests. The authors concluded that NADH is unlikely to produce cognitive improvements of the magnitude reported earlier.

Rainer M, Kraxberger E, Haushofer M, et al. J Neural Transm (Vienna), 2000. PMID 11459000

1999 / Controlled trial

Protein-rich midday meals elicited an acute increase in salivary free cortisol

Researchers measured salivary free cortisol in healthy men before and after high-protein midday meals (39% energy as protein) compared with a fasting day, and in healthy women consuming high-protein (32%) or low-protein (5%) meals. An acute increase in cortisol occurred following high-protein meals but not after the low-protein meal. The magnitude of this cortisol increase in women correlated significantly with poorer psychological well-being.

Gibson EL, Checkley S, Papadopoulos A, et al. Psychosom Med, 1999. PMID 10204975

1999 / Randomized controlled trial

Exercise and antidepressants both reduced depression scores over sixteen weeks in older adults

A 16-week randomized controlled trial evaluated 156 adults aged 50 years or older with major depressive disorder assigned to aerobic exercise, sertraline hydrochloride, or combination therapy. After 16 weeks, depression scores on HAM-D and BDI did not differ statistically among groups (P = .67), and all arms showed significant reductions. Medication produced the fastest initial response, while combination therapy showed quicker early improvement among participants who started with less severe symptoms.

Blumenthal JA, Babyak MA, Moore KA, et al. Arch Intern Med, 1999. PMID 10547175

1999 / Intervention trial (pre-post)

A low-fat diet intervention significantly reduced migraine headache frequency, intensity, duration, and medication intake in migraine patients.

A 12-week study evaluated the impact of limiting dietary fat to no more than 20 g/day in 54 migraine patients following a 28-day baseline and a 28-day run-in period. Participants significantly decreased dietary fat intake from baseline (mean 65.9 g/day) to the final 28-day postintervention period (mean 27.8 g/day, p < 0.0001). The reduction in dietary fat was associated with statistically significant decreases in headache frequency, intensity, duration, and medication intake (all p < 0.0001). A significant positive correlation was also observed between baseline fat intake and headache frequency (r = .44, p = 0.02).

Bic Z, Blix GG, Hopp HP, et al. J Womens Health Gend Based Med, 1999. PMID 10839648

1998 / Double-masked randomized clinical trial

Supplementing infant formula with DHA or DHA plus AA improved sweep VEP visual acuity and red blood cell lipid composition in term infants.

A double-masked trial evaluated term infant formula supplemented with DHA (0.35%) or DHA (0.36%) and AA (0.72%) compared to unsupplemented formula and a breast-fed reference group. Supplementation during the first 4 months produced differences in total red blood cell (RBC) lipid composition and led to better sweep VEP acuity at 6, 17, and 52 weeks of age, but not at 26 weeks. Supplemented infants showed RBC lipid composition and sweep VEP acuity similar to breast-fed infants, whereas unsupplemented infants differed significantly from breast-fed infants. Differences in acuity were not detected by forced choice preferential looking, and infants in all diet groups demonstrated similar growth rates and tolerance.

Birch EE, Hoffman DR, Uauy R, et al. Pediatr Res, 1998. PMID 9702915

1997 / Double-blind, placebo-controlled, randomized multicenter trial

In patients with moderate Alzheimer's disease, alpha-tocopherol or selegiline significantly delayed progression to primary disease endpoints in adjusted analyses.

A 2-year randomized trial assigned 341 patients with moderate Alzheimer's disease to receive selegiline (10 mg/day), alpha-tocopherol (vitamin E, 2000 IU/day), both, or placebo. In unadjusted analyses, there was no statistically significant difference in outcomes among the four groups. After adjusting for baseline Mini-Mental State Examination scores, significant delays in time to the primary outcome were observed for selegiline (median 655 days, P=0.012), alpha-tocopherol (median 670 days, P=0.001), and combination therapy (median 585 days, P=0.049) compared with placebo (median 440 days).

Sano M, Ernesto C, Thomas RG, et al. N Engl J Med, 1997. PMID 9110909

1996 / Open-label pilot trial

In an open-label trial of 17 Alzheimer's patients, coenzyme nicotinamide adenine dinucleotide (NADH) was reported to improve cognitive dysfunction scores.

An open-label trial evaluated nicotinamide adenine dinucleotide (NADH) medication in 17 patients with dementia of the Alzheimer type for 8 to 12 weeks. All evaluated patients showed improvement in cognitive dysfunction, with Mini-Mental State Examination scores improving by a mean of 8.35 points (range: 6 to 14 points) and Global Deterioration Scale scores improving by a mean of 1.82 (range: 1 to 2 points). No side effects or adverse effects were reported during observation periods exceeding a year in some patients. The authors noted that this pilot study does not allow definitive conclusions and that a double-blind placebo-controlled study is necessary.

Birkmayer JG Ann Clin Lab Sci, 1996. PMID 8834355

1996 / Multicenter, randomized, double-blind, placebo-controlled trial

Oral magnesium showed no prophylactic benefit over placebo in migraine patients.

In an interim evaluation of 69 patients with 2 to 6 migraine attacks per month, 10 of 35 patients (28.6%) taking 10 mmol magnesium twice daily responded, compared to 10 of 34 (29.4%) taking placebo. Migraine days and attacks showed no difference between groups. Mild adverse events occurred in 45.7% of the magnesium group versus 23.5% with placebo, prompting trial discontinuation.

Pfaffenrath V, Wessely P, Meyer C, et al. Cephalalgia, 1996. PMID 8902254

1996 / Controlled clinical trial

Late-afternoon ethanol intake disrupted nocturnal sleep consolidation and altered sleep EEG in middle-aged men.

Ten healthy middle-aged men were given a moderate dose of ethanol (0.55 g/kg of body weight) 6 hours before scheduled bedtime and compared to a mineral water control condition. Breath-ethanol concentrations reached zero in all subjects by bedtime. Sleep was perceived as more superficial, while sleep efficiency, total sleep time, stage 1, and REM sleep were reduced, and wakefulness doubled in the second half of the night. EEG power density was enhanced in low delta frequencies during non-REM (1.25-2.5 Hz) and REM sleep (1.25-1.5 Hz), and slow wave sleep showed power density increases in low-frequency, alpha (8.25-9.0 Hz), and sigma (12.25-13.0 Hz) bands.

Landolt HP, Roth C, Dijk DJ, et al. J Clin Psychopharmacol, 1996. PMID 8959467

1995 / Placebo-controlled trial

Morning caffeine intake (200 mg) significantly reduced sleep efficiency and total sleep time during the subsequent night in healthy men.

Nine healthy men were administered 200 mg of caffeine or placebo at 07.10 h to evaluate sleep stages and EEG power spectra during the subsequent night. Salivary caffeine levels decreased from a peak of 17 mumol/l at one hour post-intake to 3 mumol/l prior to sleep at 23.00 h. Compared to placebo, morning caffeine intake significantly reduced sleep efficiency and total sleep time. In nonREM sleep, EEG power density was suppressed in the 0.25-0.5 Hz band and enhanced in sleep spindle ranges (11.25-12.0 Hz and 13.25-14.0 Hz), while in REM sleep, EEG power density was suppressed in the 0.75-4.5 and 5.25-6.0 Hz bands.

Landolt HP, Werth E, Borbély AA, et al. Brain Res, 1995. PMID 7796154

1995 / Intervention trial with healthy control group

An 8-week cow's milk elimination diet improved behavioral symptoms in autistic patients, who also had higher milk-protein antibody levels than controls.

Researchers evaluated the efficacy of an elimination diet (free of cow's milk or other skin-test-positive foods) in 36 autistic patients over 8 weeks, while comparing food antibody levels to 20 healthy children. Patients showed a marked improvement in behavioral symptoms after 8 weeks on the elimination diet. Autistic patients also had significantly higher levels of IgA antibodies to casein, lactalbumin, and beta-lactoglobulin, as well as IgG and IgM to casein, compared with the 20 healthy controls.

Lucarelli S, Frediani T, Zingoni AM, et al. Panminerva Med, 1995. PMID 8869369

1994 / Randomized controlled trial

Maternal expectancy of sugar intake influenced ratings of child hyperactivity and parental behavior.

Thirty-five boys aged 5 to 7 whose mothers considered them sugar-sensitive participated in an interaction trial where all children received an aspartame placebo. Mothers who were led to believe their son received a large sugar dose rated their child as significantly more hyperactive than mothers told their child received placebo. Observational data showed these mothers maintained closer physical proximity and showed tendencies toward more critique, eye contact, and verbal interaction.

Hoover DW, Milich R J Abnorm Child Psychol, 1994. PMID 7963081

1994 / Controlled, single-blind clinical trial psychological analysis

RA patients responding to a vegetarian diet held lower belief in ordinary medicine, while dietary treatment reduced psychological distress.

Researchers examined psychological parameters among 53 rheumatoid arthritis patients participating in a trial of fasting and vegetarian diet compared with 71 non-participating RA patients. Participants had higher internal and lower chance scores on the MHLCS, lower belief in ordinary medicine, and higher belief in alternative treatments. Among patients randomized to the vegetarian diet, responders did not differ from non-responders on MHLCS scores, but responders had significantly lower belief in ordinary medical treatment. General Health Questionnaire scores favoured vegetarians over omnivores and responders over non-responders, indicating dietary treatment decreased psychological distress.

Kjeldsen-Kragh J, Haugen M, Førre O, et al. Br J Rheumatol, 1994. PMID 8205407

1993 / Single-dose interventional study

A broad bean pod mixture with carbidopa produced motor responses and L-dopa blood levels comparable to standard L-dopa medication in Parkinson's disease.

Researchers conducted single-dose studies of a Vicia faba (broad bean) pod mixture plus carbidopa in six patients with Parkinson's disease. Motor responses of equivalent magnitude to conventional L-dopa medication occurred in five patients, with a mean onset of 39 minutes and a mean duration of 104 minutes. Vicia faba meals produced blood L-dopa levels comparable to fasting standard tablet doses, and recovery studies showed 0.25% L-dopa per weight of bean pod mixture.

Kempster PA, Bogetic Z, Secombei JW, et al. Asia Pac J Clin Nutr, 1993. PMID 24352104

1993 / 30-week double-blind, placebo-controlled randomized crossover trial

Ascorbic acid supplementation was associated with reduced symptom severity in autistic children.

A 30-week double-blind, placebo-controlled trial evaluated ascorbic acid (8g/70kg/day) in 18 autistic children in a residential school. Participants were randomly assigned to an ascorbate-ascorbate-placebo or ascorbate-placebo-ascorbate treatment sequence, with each phase lasting 10 weeks. Weekly ratings on the Ritvo-Freeman scale showed significant group by phase interactions for total scores and sensory motor scores, indicating a reduction in symptom severity associated with ascorbic acid treatment.

Dolske MC, Spollen J, McKay S, et al. Prog Neuropsychopharmacol Biol Psychiatry, 1993. PMID 8255984

1993 / Double-blind crossover study

Aspartame challenge was linked to adverse symptoms in individuals with depression

In a crossover study, participants received 30 mg/kg/day of aspartame or placebo across 7-day periods. The trial was halted after 13 individuals completed the protocol due to severe reactions among participants with depression history. In these patients, aspartame was linked to significantly greater symptom frequency and severity compared to placebo. No difference was observed among individuals without a psychiatric history.

Walton RG, Hudak R, Green-Waite RJ Biol Psychiatry, 1993. PMID 8373935

1992 / Interventional trial

A diet rich in insoluble fiber improved motor function and plasma L-dopa bioavailability in Parkinsonian patients with marked constipation.

This study evaluated the effects of a diet rich in insoluble fiber (DRIF) on motor disability and the peripheral pharmacokinetics of oral L-dopa in Parkinsonian patients with marked constipation. The researchers observed a useful effect of DRIF on plasma L-dopa concentrations and motor function, with the greatest plasma level increases occurring early at 30 and 60 minutes after administration. Additionally, a relationship was found between improvement of constipation and higher bioavailability of L-dopa.

Astarloa R, Mena MA, Sánchez V, et al. Clin Neuropharmacol, 1992. PMID 1330307

1992 / Intervention study

Broad bean consumption increased plasma levodopa and improved clinical features in Parkinson's disease patients.

Five healthy volunteers and six patients with Parkinson's disease consumed 250 g of cooked broad beans after being without treatment for 12 hours. Over the subsequent four hours, substantial clinical improvement was observed, three patients experienced severe dyskinesias, and plasma levodopa concentrations increased.

Rabey JM, Vered Y, Shabtai H, et al. J Neurol Neurosurg Psychiatry, 1992. PMID 1527547

1992 / Laboratory experimental study (three experiments)

Repeated exposure to lemon or lime juice leads to salivary and hedonic habituation, which can be dishabituated by novel tastes or distraction.

Three laboratory experiments in humans investigated habituation and dishabituation of salivary response and hedonic ratings. In experiment 1, salivation and hedonic ratings to lemon or lime juice habituated within 10 presentations, and dishabituation occurred after a new juice was presented. Experiment 2 replicated these effects using lemon juice, showing dishabituation and a relative hedonic increase when chocolate taste was introduced. Experiment 3 demonstrated that a nontaste distractor (a video game) could both prevent habituation and act as a dishabituator after habituation occurred.

Epstein LH, Rodefer JS, Wisniewski L, et al. Physiol Behav, 1992. PMID 1615055

1992 / Interventional cohort study

A protein redistribution diet remained successful in 70% of parkinsonian patients with motor fluctuations after more than 12 months.

Forty-three carbidopa-levodopa-treated parkinsonian patients with protein-sensitive motor fluctuations were started on a protein redistribution diet. Thirty patients (70%) were still using the diet successfully after more than 12 months, with a mean duration of 33.6 months (range, 12 to 48 months). The diet was discontinued in 13 cases, but only in three patients (7%) with the most severe and complicated disease was it stopped due to limited therapeutic benefit.

Karstaedt PJ, Pincus JH Arch Neurol, 1992. PMID 1736847

1991 / Intervention trial

A protein redistribution diet reduced diurnal motor fluctuations in 5 of 16 Parkinson's patients and tended to stabilize levodopa response overall.

Sixteen parkinsonian patients with daily fluctuations in clinical response to levodopa were placed on a protein redistribution diet that was virtually protein-free until the evening meal. While on the diet, 5 out of 16 patients experienced a clear and significant benefit with a definite reduction of diurnal motor performance fluctuations. Additionally, all patients tended to show an improvement and a more constant response to levodopa treatment.

Bracco F, Malesani R, Saladini M, et al. Eur Neurol, 1991. PMID 2044618

1990 / Interventional study with 34-year follow-up

In multiple sclerosis patients, adhering to a low-fat diet for 34 years was associated with significantly less deterioration and lower death rates.

144 multiple sclerosis patients were followed while taking a low-fat diet for 34 years. Across three categories of neurological disability (minimum, moderate, severe), patients who adhered to the prescribed diet (<=20 g fat/day) experienced significantly less deterioration and much lower death rates than those consuming >20 g fat/day. The greatest benefit occurred in those with minimum disability at the start; excluding non-MS deaths, 95% of this group survived and remained physically active.

Swank RL, Dugan BB Lancet, 1990. PMID 1973220